摘要
目的:探讨金芪降糖片与盐酸吡格列酮对初发2型糖尿病患者胰岛功能的影响。方法:120例入选患者随机分为金芪降糖片组(A组)、盐酸吡格列酮组(B组)和金芪降糖片联合盐酸吡格列酮组(C组),疗程为12周。分别测定3组治疗前后空腹血糖(FPG)及餐后2h血糖(2hPG)、空腹胰岛素水平(FINS),比较胰岛素抵抗指数(HOMA-IR)及β细胞功能指数(HOMA-IS)。结果:3组治疗后FPG、2hPG和HOMA-IR治疗后低于治疗前,HOMA-IS高于治疗前,A组与B组比较差别无统计学意义(P>0.05),C组与A组和B组比较差别有统计学意义(P<0.05)。结论:改善胰岛素抵抗可能是金芪降糖片抗糖尿病作用的主要机制之一。
Objective: To investigate the effects of Jinqi melbine and acid hydroc-Pioglitazone on the functions of pancreatic island in the early type 2 diabetic patients. Methods: One hundred and twenty patients with early diabetes were randomly divided into 3 groups: Jinqi melbine group (group A), Pioglitazone group (group B) and Jinqi melbine and Pioglitazone group (group C). Fasting blood glucose (FPG), postprandial 2 h plasma glucose (2 hPG) and fasting insulin level were tested before and after treatment respectively in three groups. The effects of the glucose level on insulin resistance (HOMA-IR) was analysed by means of comparing IR index with β-cell function index(HOMA-IS). Results: The levels of FPG, 2 hPG and HOMA-IR were significantly lower after treatment compared with that before treatment in three groups. The HOMA-IS was higher after treatment than that before treatment in three groups .The different of HOMA-IS index was not seen between A and B group. The HOMA-IS index in C group was siginificantly higher compared with that in other two groups (P < 0.05). Conclusion: Improving insulin resistance is possibly a main mechanism of Jinqi melbine in treating diabetic patients.
出处
《天津医药》
CAS
北大核心
2005年第5期294-296,共3页
Tianjin Medical Journal
